methotrexate has been researched along with Scleroderma, Diffuse in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Baron, M; Baxter, CA; Nevskaya, T; Pope, JE; Ramey, DR; Zheng, B | 1 |
| Allanore, Y; Assassi, S; Baron, M; Berrocal, VJ; Clements, PJ; Denton, CP; Distler, O; Furst, DE; Giannini, EH; Johnson, SR; Khanna, D; Matucci-Cerinic, M; Mayes, MD; Merkel, PA; Phillips, K; Pope, JE; Proudman, SM; Schiopu, E; Seibold, JR; Siegel, J; Simms, RW; Steen, V; Wells, AU; Wong, WK | 1 |
| Darr-Foit, S; Elsner, P; Miguel, D; Tittelbach, J | 1 |
| Agard, C; Ahmad, Y; Akil, M; Ancuţa, C; Anderson, ME; Balbir-Gurman, A; Becker, M; Brown, E; Buch, MH; Carreira, PE; Chakravarty, K; Chung, L; Coppere, B; Czirják, L; Damjanov, N; Denton, CP; Diot, E; Distler, JHW; Distler, O; Farge, D; Fauchais, AL; Fligelstone, K; Grange, C; Gregory, WJ; Gunawardena, H; Hachulla, E; Hall, FC; Hamilton, J; Herrick, AL; Hesselstrand, R; Hudson, M; İnanç, M; Jacobsen, S; Jobanputra, P; Jordan, AC; Lanyon, P; Lunt, M; MacGregor, AJ; Madhok, R; Matucci-Cerinic, M; McHugh, N; McLaren, JS; Midtvedt, Ø; Moinzadeh, P; Mouthon, L; Müller-Ladner, U; Ochiel, R; Ong, VH; Pan, X; Pathare, S; Peytrignet, S; Proudman, S; Riemekasten, G; Roddy, J; Rudin, A; Sahhar, J; Serratrice, C; Sheeran, T; Silman, A; Stevens, W; Trad, GS; van Laar, JM; Veale, DJ; Vonk, M | 1 |
| Burger, C; Clements, PJ; Danovitch, G; Furst, DE; Khanna, D; Maranian, P; Su, TI | 1 |
| Clements, PJ; Pope, JE; Sultan, N | 1 |
| Bessis, D; Guilhou, JJ; Guillot, B; Legouffe, E | 1 |
| Altmeyer, P; Appelhans, C; Breuckmann, F; Harati, A; Kreuter, A; Rotterdam, S | 1 |
1 review(s) available for methotrexate and Scleroderma, Diffuse
| Article | Year |
|---|---|
The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma.
Topics: Dermatologic Agents; Disability Evaluation; Female; Health Status Indicators; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Penicillamine; Prognosis; Scleroderma, Diffuse; Surveys and Questionnaires; Treatment Outcome | 2004 |
3 trial(s) available for methotrexate and Scleroderma, Diffuse
| Article | Year |
|---|---|
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.
Topics: Adult; Antirheumatic Agents; Cohort Studies; Female; Humans; Logistic Models; Longitudinal Studies; Male; Methotrexate; Middle Aged; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic; Reproducibility of Results; Rheumatology; Scleroderma, Diffuse; Societies, Medical | 2016 |
Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study.
Topics: Adolescent; Adult; Aged; Female; Health Status; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Pilot Projects; Scleroderma, Diffuse; Sirolimus; Skin; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2009 |
The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma.
Topics: Dermatologic Agents; Disability Evaluation; Female; Health Status Indicators; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Penicillamine; Prognosis; Scleroderma, Diffuse; Surveys and Questionnaires; Treatment Outcome | 2004 |
5 other study(ies) available for methotrexate and Scleroderma, Diffuse
| Article | Year |
|---|---|
Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis.
Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Disease Progression; Female; Heart; Humans; Immunosuppressive Agents; Lung; Male; Methotrexate; Middle Aged; Prognosis; Registries; Scleroderma, Diffuse; Severity of Illness Index; Skin | 2020 |
Trigeminal neuropathy responding to systemic corticosteroids and methotrexate in a patient with diffuse cutaneous systemic sclerosis.
Topics: Female; Glucocorticoids; Humans; Immunosuppressive Agents; Methotrexate; Middle Aged; Prednisolone; Scleroderma, Diffuse; Trigeminal Nerve Diseases | 2017 |
Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS).
Topics: Adult; Antibodies, Antinuclear; Autoantibodies; Cohort Studies; Cyclophosphamide; DNA Topoisomerases, Type I; Early Medical Intervention; Europe; Female; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Nuclear Proteins; Prospective Studies; RNA Polymerase III; Scleroderma, Diffuse; Severity of Illness Index; Survival Rate; Treatment Outcome | 2017 |
Gemcitabine-associated scleroderma-like changes of the lower extremities.
Topics: Acetaminophen; Amitriptyline; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Carcinoma, Transitional Cell; Cisplatin; Clonazepam; Deoxycytidine; Dermis; Doxorubicin; Edema; Gemcitabine; Humans; Infusions, Intravenous; Leg; Lung Neoplasms; Male; Methotrexate; Middle Aged; Morphine; Scleroderma, Diffuse; Vinblastine | 2004 |
Failure of low-dose methotrexate in the treatment of scleredema diabeticorum in seven cases.
Topics: Adult; Aged; Dermatologic Agents; Diabetes Mellitus, Type 1; Female; Humans; Male; Methotrexate; Middle Aged; Scleroderma, Diffuse; Treatment Failure | 2005 |